Spinocerebellar Ataxia Type 3 Overview

Save information for later
Sign Up

Learn About Spinocerebellar Ataxia Type 3

What is the definition of Spinocerebellar Ataxia Type 3?
Spinocerebellar ataxia 3 (SCA3) is a rare, inherited form of ataxia. Signs and symptoms may begin between childhood and late adulthood and vary greatly. Symptoms may include slowly progressive clumsiness in the arms and legs; a manner of walking (gait) that may be mistaken for drunkenness; difficulty speaking and swallowing; impaired eye movements or vision; and lower limb spasticity. Some people with SCA3 develop dystonia or symptoms similar to those of Parkinson's disease; twitching of the face or tongue; nerve damage (neuropathy); or problems with urination and the autonomic nervous system. SCA3 is caused by a genetic change in the ATXN3 gene and inheritance is autosomal dominant.
What are the alternative names for Spinocerebellar Ataxia Type 3?
  • Spinocerebellar ataxia 3
  • Azorean neurologic disease
  • MJD
  • Machado-Joseph disease
  • Nigrospinodentatal degeneration
  • SCA3
  • Spinocerebellar atrophy type 3
  • Spinopontine atrophy
Who are the top Spinocerebellar Ataxia Type 3 Local Doctors?
Advanced in Spinocerebellar Ataxia Type 3
Dr. Peter Hedera
Neurology | Neurosurgery
Advanced in Spinocerebellar Ataxia Type 3
Dr. Peter Hedera
Neurology | Neurosurgery

University Of Louisville Physicians Inc

401 E Chestnut St, 
Louisville, KY 
 (1.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Hedera is a Neurologist and a Neurosurgery provider in Louisville, Kentucky. Dr. Hedera and is rated as an Advanced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 3. His top areas of expertise are Drug Induced Dyskinesia, Mcleod Neuroacanthocytosis Syndrome, Huntington Disease, and Wilson Disease. Dr. Hedera is currently accepting new patients.

Advanced in Spinocerebellar Ataxia Type 3
Dr. Mohammad S. Alsorogi
Neurology
Advanced in Spinocerebellar Ataxia Type 3
Dr. Mohammad S. Alsorogi
Neurology

Community Medical Associates Inc

825 Barret Ave, 
Louisville, KY 
 (1.9 mi)
502-272-5165
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mohammad Alsorogi is a Neurologist in Louisville, Kentucky. Dr. Alsorogi and is rated as an Advanced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 3. His top areas of expertise are Dry Mouth, Drug Induced Dyskinesia, Migraine, and Relapsing Multiple Sclerosis (RMS). Dr. Alsorogi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Spinocerebellar Ataxia Type 3
Dr. Disha U. Shah
Neurology
Experienced in Spinocerebellar Ataxia Type 3
Dr. Disha U. Shah
Neurology

University Of Louisville Physicians Inc

201 Abraham Flexner Way, Suite 1200, 
Louisville, KY 
 (0.9 mi)
502-583-8383
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Disha Shah is a Neurologist in Louisville, Kentucky. Dr. Shah and is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 3. Her top areas of expertise are Migraine, Essential Tremor, Memory Loss, and Cerebellar Degeneration. Dr. Shah is currently accepting new patients.

View All Doctors
What are the latest Spinocerebellar Ataxia Type 3 Clinical Trials?
A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease
A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease
Enrollment Status: Recruiting
Publish Date: April 08, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be admini...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Coordination of Rare Diseases at Sanford
Coordination of Rare Diseases at Sanford
Enrollment Status: Recruiting
Publish Date: January 19, 2024

Summary: CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, in...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center